(Q50594918)

16 March 2018

title

Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. (English)

1 reference

16 March 2018

main subject

phase I clinical trial

0 references

1 reference

Zhiyu Chen

1

1 reference

16 March 2018

Weijian Guo

2

1 reference

16 March 2018

Junning Cao

3

1 reference

16 March 2018

Fangfang Lv

4

1 reference

16 March 2018

Wen Zhang

5

1 reference

16 March 2018

Lixin Qiu

6

1 reference

16 March 2018

Wenhua Li

7

1 reference

16 March 2018

Dongmei Ji

8

1 reference

16 March 2018

Sheng Zhang

9

1 reference

16 March 2018

Zuguang Xia

10

1 reference

16 March 2018

Jiachen Wang

11

1 reference

16 March 2018

Jin Li

12

1 reference

16 March 2018

publication date

9 January 2015

1 reference

16 March 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

16 March 2018

volume

75

1 reference

16 March 2018

issue

3

1 reference

16 March 2018

page(s)

547-557

1 reference

16 March 2018

https://scigraph.springernature.com/pub.10.1007/s00280-014-2656-9

exact match

0 references

cites work

Challenges to effective cancer control in China, India, and Russia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Targeted treatments in colorectal cancer: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

Feasibility and short-term outcome of adjuvant FOLFOX after resection of colorectal liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2656-9

10.1007/S00280-014-2656-9

21 January 2018

Identifiers

DOI

1 reference

16 March 2018

PubMed ID

25572362

1 reference

16 March 2018